Clinical Trials: Neoplasm Metastasis

Birmingham : University of Alabama At Birmingham

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Huntsville : Clearview Cancer Center

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6

Anchorage : Providence Alaska Medical Center Cancer Research

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Glendale : Arizona Center for Cancer Care

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Scottsdale : Updated

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Scottsdale : TGen Clinical Research Services at Scottsdale Healthcare

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Scottsdale : Scottsdale Medical Imaging

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Scottsdale : Pinnacle Oncology Hematology

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

View More »

Tucson : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Fayetteville : Research Site Updated

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Hot Springs : Heritage Physician Group Oncology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Hot Springs : Genesis Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Jonesboro : NEA Baptist Clinic

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Springdale : Highlands Oncology Group

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Anaheim : Research Site Updated

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Anaheim : Pacific Cancer Medical Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Arcadia : Shapiro, Stafford & Yee & Polanski

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Concord : Bay Area Cancer Research Group

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Duarte : City of Hope Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

View More »

Encinitas : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Fountain Valley : Pacific Coast Hem/Onc

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Freemont : Silicon Valley Imaging

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Fullerton : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Greenbrae : Marin Cancer Care

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Greenbrae : California Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

La Jolla : University of California San Diego

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

La Jolla : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

La Jolla : Univ. of California at San Diego Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

La Jolla : Univ. of California San Diego

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

La Verne : Wilshire Oncology Medical Group

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Loma Linda : Loma Linda University Medical Center

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Long Beach : Pacific Shores Medical Group

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Los Angeles : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Los Angeles : VA West Los Angles Medical Center

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Los Angeles : Cedar-Sinai Medical Center

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Los Angeles : UCLA

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Los Angeles : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Los Angeles : University of Southern California Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Mission Hills : North Valley Hematology/Oncology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Montebello : Clinical Trials and Research Associates, Inc.

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Orange : St. Joseph Hospital

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Orange : Medical Oncology Care Associates

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Oxnard : Ventura County Hematology and Oncology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Palm Springs : Comprehensive Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Pomona : Swarma Chanduri, M.D.

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Rancho Mirage : Access Clinical Research

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Rancho Mirage : Desert Cancer Care

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Rancho Mirage : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Redondo Beach : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Sacramento : Research Site

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Sacramento : Radiology Associates of Sacramento/Sutter Cancer Center

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6

Sacramento : UC Davis Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

San Diego : Kaiser Permanente-San Diego

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

San Francisco : University of California At San Francisco

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Santa Maria : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study of LY3007113 in Patients With Advanced Cancer

Santa Rosa : Redwood Regional Medical Group, Inc.

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Stanford : Stanford University Medical Center

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Stanford : Stanford University Medical Center

ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

Stanford : Stanford University Medical Center

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Stanford : Stanford University School of Medicine

Phase II Gemzar, Taxol & Avastin Combination as 1st Line Tx for Metastatic Breast CA

Sylmar : Olive View UCLA Medical

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Vallejo : Kaiser Permanente Medical Center - Vallejo

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Aurora : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Denver : Denver Health Medical Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

New Haven : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Norwich : Eastern Connecticut Hematology & Oncology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Newark : CCOP - Christiana Care Health Services

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Boca Raton : University MRI & Diagnostic Imaging Centers

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Boynton Beach : Research Site Updated

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Brooksville : Pasco Hernando Oncology Associates, PA

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Coral Springs : Northwest Hematology and Oncology Associates Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Fort Lauderdale : Broward Oncology Associates

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

View More »

Ft. Myers : Florida Cancer Specialists

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Jacksonville : Baptist Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Jupiter : Jupiter Medical Center-Clinical Research Office

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Melbourne : Osler Medical, Inc.

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

New Port Richey : Pasco Hernando Oncology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Orlando : Research Site

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Orlando : M.D. Anderson Cancer Center - Orlando

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Tamarac : Elizabeth Tan-Chiu, MDPA

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Tampa : Research Site

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Tampa : Moffitt Cancer Center

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Tampa : Moffitt Cancer Center Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Tampa : H. Lee Moffitt Cancer Center

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Tampa : H. Lee Moffitt Cancer Center & Research Institute

Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors

Athens : Northeast Georgia Cancer, LLC Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Atlanta : Emory University

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6

Atlanta : Northside Hospital/GA Cancer Specialists

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6

Atlanta : Winship Cancer Institute at Emory University

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Atlanta : Emory University Winship Cancer Institute

Pasireotide, Everolimus and Selective Internal Radioemobilization Therapy for Unresectable Hepatic Metastases

View More »

Columbus : Amos Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Gainesville : Northeast Georgia Medical Center

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Lawrenceville : Suburban Hematology-Oncology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Savannah : SouthCoast Imaging Center

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Berwyn : Vanguard Health

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Chicago : University of Chicago

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Chicago : University of Chicago

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Chicago : The Robert H. Lurie Comprehensive Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Chicago : University of Illinois at Chicago

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

View More »

Chicago : Weiss Memorial Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Chicago : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Evanston : CCOP - NorthShore University HealthSystem

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Evanston : Evanston Northwestern Healthcare

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Harvey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Harvey : Ingalls Memorial Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Harvey : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Harvey : Ingalls Memorial Hospital Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Harvey : Ingalls Memorial Hospital

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Naperville : Edward Hospital

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Naperville : Edward Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Quincy : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Skokie : Clintell - Midwest Cancer Research Group

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Fort Wayne : Research Site Updated

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Indianapolis : Indiana University Simon Cancer Center

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Indianapolis : Investigative Clinical Research of Indiana

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Indianapolis : Indiana University Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Indianapolis : Indiana University Melvin and Bren Simon Cancer Center

Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors

View More »

New Albany : Cancer Care Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Terre Haute : Associated Physicians and Surgeons, LLC

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Terre Haute : Providence Medical Group

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Iowa City : University of Iowa

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Iowa City : University of Iowa Hospital

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Sioux City : Siouxland Hematology-Oncology Associates, L.L.P.

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Waterloo : Cedar Valley Medical Associates

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Overland Park : Kansas City Cancer Centers

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Salina : Mowery Clinic LLC Tammy Walker Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Topeka : Cotton O'Neill Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Wichita :

A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

Wichita : Cancer Center of Kansas

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

View More »

Witchita : Cancer Center of Kansas Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Hazard : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Hazard : Kentucky Cancer Clinic

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Louisville : NortonHealthcare, Inc.

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Louisville : University of Louisville

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6

Louisville : University of Louisville

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

View More »

Paducah : Research Site Updated

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Alexandria : Cabrini Center for Cancer Care

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Lafayette : Southwest Oncology Associates, Ltd.

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Shreveport : LSUMC Feist-Weiller Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Shreveport : Pfizer Investigational Site

Open Label Extension In Cancer Patients

Baltimore : Johns Hopkins University

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Baltimore : Johns Hopkins University

A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Baltimore : Franklin Square Hospital Center

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Baltimore : Research Site Updated

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Baltimore : The Harry and Jeannette Weinberg Cancer Institute at Franklin Square

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

View More »

Baltimore : University of Maryland/Marlene and Stewart Greenebaum Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Baltimore : St. Agnes Hospital Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Baltimore : Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer

Baltimore : University of Maryland Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bethesda : Research Site Updated

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Bethesda : Center for Cancer and Blood Disorders

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Bethesda : National Capital Clinical Research Consortium

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Frederick : Frederick Memorial Hospital

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Glen Burnie : Greenbaum Cancer Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Salisbury : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Boston : Dana Farber/Brigham and Women's Cancer Center

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

Boston : Dana Farber Cancer Institute

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Boston : Dana Farber Cancer Institute

A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Boston : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Boston : Dana-Farber Cancer Institute

Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases

View More »

Boston : Massachusetts General Hospital

Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases

Boston : Beth Israel Deaconess Medical Center

Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases

Boston : Beth Israel Deaconess Medical Center`

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Boston : Massachusetts General Hospital

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Boston : Dana-Farber Cancer Institute

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Boston : Dana-Farber Cancer Institute

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

Boston : Beth Israel Deaconess Medical Center

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

Boston : Brigham and Women's Hospital

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Boston : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Boston : Dana Farber Cancer Institute Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Boston : Dana Farber Cancer Institute

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Methuen : Caritas Holy Family Hospital

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Ann Arbor : University of Michigan

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Ann Arbor : University of Michigan Health System

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Ann Arbor : University of Michigan Health System

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Ann Arbor : University of Michigan

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

Detriot : Karmanos Cancer Institute

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

View More »

Detroit : Updated

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Detroit : Site Reference ID/Investigator# 19021

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Detroit : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Detroit : Henry Ford Health System

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Detroit : Henry Ford Health System/Division of Hematology/Oncology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Detroit : Wayne State University/Karmanos Cancer Institute

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Detroit : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Detroit : Henry Ford Hospital Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Detroit : Karmanos Cancer Institute

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Flint : McLaren Regional Medical Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Grand Rapids : CCOP - Grand Rapids Clinical Oncology Program

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Grand Rapids : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Grosse Pointe : St. John Hospital and Medical Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Royal Oak : CCOP, William Beaumont Hospital

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Royal Oak : William Beaumont Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Saint Joseph : Oncology Care Associates

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Duluth : St. Luke Whiteside Research

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Duluth : Duluth Clinic Cancer Center SMDC Health System

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Minneapolis : Fairview Clinical Trials Services

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Minneapolis : University of Minnesota Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Minneapolis : Virginia Piper Cancer Institute

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

View More »

Minneapolis : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Robbinsdale : Hubert H. Humphrey Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Saint Louis Park : CCOP - Metro-Minnesota

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

St. Louis Park : Research Site

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Hattiesburg : Hattiesburg Clinic

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Pascagoula : Singing River Hospital

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Tupelo : Hematology and Oncology Assoc. at Bridgeport

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6

Chesterfield : St. Luke's Hospital

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Jefferson City : Capitol Comprehensive Cancer Care Clinic

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Kansas City : Saint Luke's Hospital

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Saint Louis : John Cochran Veterans Administration

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Saint Louis : Saint Louis University

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

View More »

Springfield : Research Site Updated

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

St Louis : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

St. Louis : Washington University/Alvin J. Siteman Cancer Center

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6

St. Louis : St. Louis Cancer & Breast Institute

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

St. Louis : The Center for Cancer Care Research

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Billings : Hematology Oncology Centers of the Northern Rockies

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Lincoln : Nebraska Hematology-Oncology, PC

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Omaha : Nebraska Methodist Hospital

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Omaha : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Lebanon : Dartmouth-Hitchcock Medical Center

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Lebanon : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Portsmouth : Portsmouth Regional Hospital

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Basking Ridge : Memorial Sloan-Kettering Cancer Center at Basking Ridge

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Belleville : Essex Oncology of North Jersey

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Cherry Hill : The Center for Cancer and Hematologic Disease

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Livingston : Saint Barnabas Medical Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Morristown : Hematology-Oncology Associates of Northern NJ

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

View More »

New Brunswick : Robert Wood Johnson University Hospital

Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)

New Brunswick : The Cancer Institute of New Jersey

Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)

Somerville : Somerset Hematology Oncology Associates

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Teaneck : Holy Name Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Albuquerque : New Mexico Oncology Hematology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Armonk : Advanced Oncology Associates

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Bronx : Montefiore Medical Center

Phase 2 Study of Thermodox as Adjuvant Therapy With Radiofrequency Ablation (RFA) in Treatment of Colorectal Liver Metastases (CRLM)

Bronx : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Brooklyn : SUNY Downstate Medical Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer

View More »

Corning : Guthrie Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Fresh Meadows : Clinical Research Coordinator Queens Medical Associates, PC

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Great Neck : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Kingston : Benedictine Hospital

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

New Hyde Park : Arena Oncology Associates

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

New York : Memorial Sloan-Kettering Cancer Center

A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

New York : Memorial Sloan Kettering Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

New York : Columbia University Medical Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

New York : Weill Cornell Medical College

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

New York : New York Presbyterian Weill Cornell

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

New York : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

New York : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

New York : Memorial Sloan Kettering Cancer Center

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer

New York city : Department of Radiation oncology, Memorial Sloan Kettering Cancer Center

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

Rochester : University of Rochester/Medical Center James P. Wilmot Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Rockville Centre : Memorial Sloan-Kettering Cancer Center at Mercy Medical Center

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Burlington : Alamance Regional Medical Center Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Chapel Hill : University of North Carolina-CH Lineberger Comprehensive Cancer Center

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Chapel Hill : UNC Lineberger Comprehensive Cancer Center

A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

Chapel Hill : Univ. of North Carolina Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Charlotte : Carolinas Healthcare System

A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

View More »

Charlotte : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Charlotte : Carolinas Hematology-Oncology Associates

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Carolinas Hematology-Oncology Associates - Ballantyne

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Carolinas Hematology-Oncology Associates - University

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Carolinas Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Levine Cancer Institute - Blumenthal Cancer Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Mecklenburg Medical Group - Morehead

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Mecklenburg Medical Group - Pineville

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Mecklenburg Medical Group - South Park

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Concord : Northeast Oncology Associates

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Concord : Northeast Oncology Associates

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Durham : Duke University

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Durham : Duke University Medical Center

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Durham : Duke University

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Durham : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Durham : Duke University Medical Center

Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

Durham : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Goldsboro : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

High Point : Research Site Updated

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Huntersville : Carolina BioOncology Institute

Isolation and Culture of Circulating Tumor Cells From Peripheral Blood

Monroe : Mecklenburg Medical Group - Carolinas Cancer Associates

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Winston Salem : Research Site

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Winston Salem : University of Wake Forest Baptist Medical Center

Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

Bismarck : Research Site

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Grand Forks : Altru Health Systems

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Akron : Summa Health System/Cooper Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Barberton : Barberton Citizens Hospital-Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Canton :

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Cincinnati : Oncology Hematology Care, Inc

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Cleveland : Cleveland Clinic

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

View More »

Cleveland : University Hospitals Seidman Cancer Center Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Cleveland : Cleveland Clinic Hospital

Phase 2 Study of Thermodox as Adjuvant Therapy With Radiofrequency Ablation (RFA) in Treatment of Colorectal Liver Metastases (CRLM)

Columbus : Research Site

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Columbus : Hematology Oncology Consultants

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Columbus : Riverside Methodist Hospital

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Dayton : CCOP, Dayton, OH

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Dayton : Dayton Clinical Oncology Program

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Mansfield : Ohio Cancer Specialists

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Middletown : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Wooster : Trilogy Cancer Care

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Youngstown : Forum Health Cancer Care Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Bend : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Coos Bay : North Bend Medical Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Portland : Providence Portland Medical Center/Providence Cancer Center

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6

Beaver : UPMC Cancer Center Beaver

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Coudersport : Patterson Cancer Care Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Greensburg : UPMC Cancer Center Arnold Palmer at Mountain View

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Hershey : Cheshire Medical Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Hershey : Hershey Medical Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

View More »

Lancaster : Lancaster Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Philadelphia : Updated

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Philadelphia : Research Site

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Philadelphia : Updated

A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Philadelphia : Thomas Jefferson University Hospital

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Philadelphia : Fox Chase Cancer Center

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Philadelphia : Thomas Jefferson University

Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases

Philadelphia : Fox Chase Cancer Center

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Pittsburgh : University of Pittsburgh Medical Center

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Pittsburgh : University of Pittsburgh

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Pittsburgh : Allegheny Cancer Center at Allegheny General Hospital

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Pittsburgh : NSABP Foundation, Inc.

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Pittsburgh : Magee-Womens Hospital

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Pittsburgh : UPMC Shadyside Radiation Oncology

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

Pittsburgh : University of Pittsburgh Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Pittsburgh : UPMC Hillman Cancer Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Pittsburgh : UPMC Cancer Center Passavant

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Pittsburgh : Hillman Cancer Center

Study of Outcomes of Radiofrequency Ablation of Lung Tumors

Sayre : Guthrie Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Uniontown : UPMC Cancer Center Uniontown

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Wynnewood : Mainline Oncology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Providence : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Providence : Rhode Island Hospital

Phase 2 Study of Thermodox as Adjuvant Therapy With Radiofrequency Ablation (RFA) in Treatment of Colorectal Liver Metastases (CRLM)

Charleston : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Columbia : M. Francisco Gonzalez, M.D.

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Santee : Santee Hematology/Oncology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Spartanburg : CCOP - Upstate Carolina

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Chattanooga : Chattanooga Oncology Hematology Associates

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Collierville : Family Cancer Center

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Knoxville : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Memphis : The West Clinic Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Nashville : Vanderbilt University

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

View More »

Nashville : Sarah Cannon Research Institute

A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers

Nashville : Tennessee Oncology, PLLC

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Nashville : Tennessee Oncology Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Nashville : Tennessee Oncology

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Dallas : UT Southwestern Medical Center at Dallas

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Dallas : Mary Crowley Cancer Research Centers Updated

Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer

Dallas : Mary Crowley Cancer Research Centers Updated

Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases

Fort Worth : The Center for Cancer and Blood Disorders

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Fort Worth : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

View More »

Houston : UT MD Anderson Cancer Center

4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis

Houston : MD Anderson Cancer Center

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Houston : UT MD Anderson Cancer Center

Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy

Houston : UT MD Anderson Cancer Center

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Houston : MD Anderson Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Houston : University of Texas MD Anderson Cancer Center

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Houston : University of Texas M.D. Anderson Cancer Center

Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases

Houston : University of Texas MD Anderson Cancer Center

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

Houston : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Paris : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

San Antonio : UTHSC- CTRC and Institute for Drug Development

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

San Antonio : South Texas Accelerated Research Therapeutics (START)

A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers

San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study of LY3007113 in Patients With Advanced Cancer

San Antonio : Cancer Care Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Temple :

A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

Salt Lake : University of Utah School of Medicine

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Salt Lake City : Updated

A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Salt Lake City : Utah Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Salt Lake City : St. Mark's Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Burlington : Vermont Cancer Center at University of Vermont

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Abingdon : Cancer Outreach Associates, P.C.

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Charlottesville : University of Virginia Health System

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Charlottesville : University of Virginia

ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

Everett : Providence Everett Medical Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Seattle : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Seattle : Swedish Cancer Institute

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Seattle : Seattle Cancer Care Alliance

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

View More »

Seattle : University of Washington

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Spokane : Rockwood Clinic

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Spokane Valley : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Tacoma : Updated

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Madison : University Of Wisconsin

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Milwaukee : Medical College of Wisconsin

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Milwaukee : Froedtert Memorial Lutheran Hospital

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6

Milwaukee : Clinical Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Milwaukee : Medical College of Wisconsin

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

View More »

Milwaukee : Aurora St. Luke's Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Milwaukee : Medical College of Wisconsin/Froedtert Memorial Lutheran Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Buenos Aires : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Buenos Aires : Hospital Italiano de Buenos Aires

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6

Cordoba : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

La Plata : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Mendoza : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

View More »

Quilmes : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Rosario : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Adelaide : Royal Adelaide Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bedford Park : Flinders Medical Centre

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bentleigh East : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Darlinghurst : St. Vincent's Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

East Bentleigh : Monash Medical Centre

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

View More »

Elizabeth Vale : Lyell McEwin Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Footscray : Research Site

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Footscray : Western Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Frankston : Peninsula Oncology Centre

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Herston : Royal Brisbane and Women's Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Hobart : Royal Hobart Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Kogarah : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Kurralta Park : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Melbourne : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Melbourne : Peter MacCallum

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Nedlands : Sir Charles Gairdner Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Nedlands : Hollywood Private Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Noble Park : South Eastern Private

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Parkville : Research Site

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Parkville : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Perth : Mount Medical Centre

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Perth : Royal Perth Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Ringwood : Ringwood/Knox Private

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Ringwood East : Maroondah Public

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

South Brisbane : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Southport : Gold Coast Health Service District

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

St Leonards : Royal North Shore Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Westmead : Westmead Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Woodville South : Queen Elizabeth II Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Woodville South : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Woolloongabba : Princess Alexandra Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Graz : Gynaegological Medical University Graz

Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer

Graz : Medical University Graz, Oncology

Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer

Graz : Graz Medical University

Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.

Innsbruck : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Innsbruck : Medical University of Innsbruck

Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer

View More »

Linz : PET-CT Linz - St. Vicent's Hospital

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Linz : General Hospital Linz

Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer

Linz : Hospital BHS Linz, Coop. Study Group

Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer

Salzburg : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

St. Veit a. d. Glan : Ordination Dr. Wette

Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer

Steyr : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Vienna : Medical University of Vienna-General Hospital Vienna

Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer

Wels : Klinikum Wels-Grieskirchen GmbH

Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer

Wien : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Aalst : OL Vrouw Ziekenhuis Aalst Gastro-Enterologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Antwerp : Universitair Ziekenhuis Antwerpen

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Antwerp : Antwerp University Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Antwerpen : ZNA Middelheim

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bonheiden : Imelda Ziekenhuis GI Clinical Research Centre

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

View More »

Bornem : Sint-Josef Ziekenhuie (Campus Bornem)

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Brussels : Updated

A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Brussels : Jules Bordet Institute

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Brussels : Institut Jules Bordet - Centre de Tumeurs d'ULB

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bruxelles : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Bruxelles : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Charleroi : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Edegem : Updated

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Edegem : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Gent : Universiteits Ziekenhuis Gent

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Gent : AZ Maria Middelares

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Gent : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Haine-Saint-Paul : Hospital de Jolimont

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Leuven : Research Site

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Leuven : UZ Leuven, Campus Gasthuisberg

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Leuven : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Leuven : University Hospitals Leuven, Catholic University

Liver-PILP First-in-Man

Leuven : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Libramont : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Liege : Centre Hospitalier Universitaire de Liege

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Liege : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Liège : Research Site

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Liège : Clinique Saint-Joseph

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Mechelen : VZW Emmaus St. Maarten Ziekenhuis Mechelen and St. Marten Ziekenhuis Duffel

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Reet : AZ Heilige Familie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Sint-Niklaas : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Wilrijk : Updated

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Wilrijk : Research Site

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Wilrijk : Updated

A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Wilrijk : Sint-Augustinus Ziekenhuis

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Wilrijk : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Curitba : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Goiânia/Go : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Ijuí : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

ItajaÃ- : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Porto Alegre : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

View More »

Porto Alegre : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Ribeirão Preto : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Ribeirão Preto/Sp : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

São Paulo : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Salvador : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Santo Andre : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Sao Jose Do Rio Preto : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Plovdiv : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Sofia : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Stara Zagora : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Varna : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Edmonton : 1200.67.11001 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Greenfield Park : 1200.67.11003 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Montreal : 1200.67.11002 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Oshawa : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Ottawa : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

View More »

Québec : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Quebec : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Québec : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Toronto : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Toronto : Local Institution

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Toronto : University Health Network-Princess Margaret Hospital

Comparison of Primovist-enhanced MRI, Diffusion Weighted MRI and Multidetector CT of Colorectal Liver Metastases

Toronto : Toronto General Hospital

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Toronto : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Toronto : Sunnybrook Updated

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Toronto : 1200.67.11004 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Toronto : Sunnybrook Health Sciences Centre

Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases

Toronto : Sunnybrook Health Sciences Centre

Radiosensitization of AVASTIN® (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis

Vancouver : Local Institution

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Vancouver : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Vancouver : University of British Columbia

Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases

Paraiso : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Temuco : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Beijing : Peking University, People's Hospital

Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis

Beijing : Peking University, School of Oncology

Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis

Beijing : Beijing Cancer Hospital

Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis

Chengdu : West China Hospital

Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Lianyungang : The First People's Hospital of Lianyungang

Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases

Floridablanca-Santander : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Montería : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Split : Clinical Hospital Split, Center of oncology

Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer

Split : Center of oncology

Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer

Brno : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Hradec Kralove : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Olomouc : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Praha 2 : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Praha 5 : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Aalborg : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Aarhus : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Herlev : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Odense : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Helsinki : 1200.67.35801 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

HUS : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Kuopio : 1200.67.35804 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Lahti : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Oulu : Dept of Oncology, Oulu University Hospital

Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients

View More »

Tampere : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Tampere : 1200.67.35802 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Turku : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Turku : 1200.67.35803 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Aix En Provence : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Amiens : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Angers : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Arras : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Avignon : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

View More »

Belfort : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Besançon Cedex : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Besancon : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Besançon : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Beziers : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Bordeaux : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Bordeaux : CHU de Bordeau

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bordeaux : CHU de Bordeaux, Hôpital Saint-André

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Bordeaux : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Boulogne-Billancourt : Hôpital Ambroise Paré

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Bourg En Bresse : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Brest cedex : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Caen : Centre François Baclesse

Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis

Caen Cedex 05 : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Caen Cedex 05 : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Caluire Et Cuire : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Cherbourg Octeville : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Clermont Ferrand Cedex 1 : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Clermont-Ferrand : Centre Jean Perrin

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Clermont-Ferrand cedex 1 : 1200.67.33010 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Colmar : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Cornebarrieu : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

DAX : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Dechy : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Dijon : Centre Georges François Leclerc

Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas

Dijon : Centre Georges François Leclerc

Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Fluorouracil Plus Mitomycin

Druex : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Freyming Merlebach : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Gien : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Gleize : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

La Chaussee St Victor : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

La Roche Sur Yon : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

La Roche Sur Yon Cedex 9 : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

La Tronche : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

La Tronche : Hospitalier Universitaire de Grenoble C.H.U.

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Lille : Centre Oscar Lambret

CyberKnife® for Hepatic Metastases From Colorectal Cancer

Lille : CHRU de Lille, Hôpital Claude Huriez

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Lille Cedex : 1200.67.33008 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Limoges : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Limoges Cedex : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Longjumeau : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Longjumeau : Centre Hospitalier General de Longjumeau

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Lorient : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Lormont : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Lyon : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Lyon Cedex 08 : 1200.67.33001 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

LYON Cedex 08 : Centre Léon Bérard

Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Infiltrations

Marseille : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Marseille : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Marseille Cedex 09 : 1200.67.33004 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Meaux : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Metz Tessy : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Montbeliard : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Mont-de-marsan : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Montelimar : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Montfermeil : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Montpellier Cedex 5 : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Mougins : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Nancy : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Nancy : Alexis Vautrin Cancer Center

CyberKnife® for Hepatic Metastases From Colorectal Cancer

Nancy : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Nantes Cedex 2 : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Narbonne : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Nice : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Nice : Hopital de l'Archet II, CHU de Nice

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Nice Cedex 02 : 1200.67.33011 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Paris : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Paris : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Paris : Hospital European Georges Pompidou

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Paris : 1200.67.33003 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Paris : Hôpital Cochin

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Paris : Hôpital Européen Georges Pompidou

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Paris : Institut Curie

Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis

Paris Cedex 05 : 1200.67.33002 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Paris cedex 13 : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Perpignan : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Pessac : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Pessac Cedex : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Pierre Benite Cedex : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Reims : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Reims Cedex : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Rennes : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Rennes Cedex : Centre Eugene Marquis

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Rouen : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Rouen : Centre Henri Becquerel

Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis

Saint Gregoire : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Saint Herblain Cedex : 1200.67.33005 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Saint Jean : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Saint Priest En Jarez Cedex : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Saint-Grégoire : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

St Herblain : Centre René Gauducheau

Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis

Strasbourg : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Strasbourg : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Strasbourg : University Hospital of Strasbourg

Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases

Toulouse : CHU Toulouse

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Toulouse : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Tours : Hopital Bretonneau

CyberKnife® for Hepatic Metastases From Colorectal Cancer

Vannes : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Vichy : Updated

An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)

Villejuif : Chronotherapy Unit, Medical Oncology Department, Paul Brousse Hospital

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Villejuif : Institut Gustave Roussy

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Villejuif : Institut Gustave-Roussy

Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer

Villejuif cedex : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Tbilisi : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Tbilisi : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Altstadt : Internistische Gemeinschaftspraxis

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Berlin : Charite Campus Virchow Klinikum

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Berlin : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Berlin : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Bonn : Neurologische Universitaetsklinik Bonn

A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain

View More »

Bonn : Braxiskooperation Bonn, Fachartze fur Innere Medizin

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bonn : Johanniterkrankenhaus Bonn

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bonn : Universitaetsklinikum Bonn

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Brandenburg : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Dresden : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Erlangen : 1200.67.49002 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Essen : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Essen : Gemeinschaftspraxis Hamatologie und internistische Onkologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Essen : Kliniken Essen Mitte

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Essen : 1200.67.49008 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Frankfurt : Universitat Frankfurt Institute fur Diagnostic und Interventionelle Radiologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Frankfurt : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Fuerth : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Halle (Saale) : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Hamburg : Universitastsklinikum Saarland

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Hamburg : Asklepios Klinik Altona, Abt. Radiologie, Neuroradiologie, Nuklearmedizin

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Hannover : 1200.67.49005 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Heidelberg : 1200.67.49006 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Herne : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Holzkirch : Praxisgemeinschaft Dr. med. Peter Sandor und Peter Kohl

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Ingolstadt : Onklogische Praxis Dr. Gerald Gehbauer

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Karlsruhe : Klinikum Karlsruhe, Stadtisches Klinikum Karlsruhe, Zentralinstitut fur Bildgebende Diagnostik

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Kiel : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Koeln : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Köln : 1200.67.49001 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Luebeck : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Münster : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Magdeburg : Klinikum Magdeburg GmbH, Klinik für Hämatologie/Onkologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Magdeburg : Schwerpunktpraxis fur Hamatologie und Onkologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Magdeburg : Universitaetsklinikum Magdeburg

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Magdeburg : Clinic for Radiology and Nuclear Medicine

Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy

Magdeburg : Clinic for Radiology and Nuclear Medicine

Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity

Mainz : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Mainz : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Mannheim : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Marburg : Universitatsklinikum GieBen und Marburg

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Marburg : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Muenchen : Klinikum Bogenhausen

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Muenchen : Klinikum der Universitaet Muenchen

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Muenchen : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Munchen : Schwerpunktspraxis fur Hamatologie und Internistische Onkologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Munchen : Hamato-Onkologische Schwerpunktspraxis

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Munchen : Klinikum rechts der Isar der TU Munchen

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

München : 1200.67.49007 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Munich : University of Munich - Klinikum Grosshadern

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

Munich : University of Munich - Klinikum der Universitaet Muenchen

Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC

Oldenburg : 1200.67.49003 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Ravensburg : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Tübingen : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Tübingen : 1200.67.49004 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Velbert : Praxis fur Hamatologie und Internnistische Onkologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Velbert : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Villingen-Schwenningen : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Weilheim : Schwerpunktspraxis und Tagesklinik Dr. Perker/Dr. Sandherr

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Wiesbaden : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Witten : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Wuerselen : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Wuerzburg : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Athens : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Athens : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Heraklion : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

N. Kifisia, Athens : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Neo Faliro : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

View More »

Patra : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Patra : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Peiraius : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Thessaloniki : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Thessaloniki : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Kowloon : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Pokfulam : GSK Investigational Site

Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib

Sha Tin : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Tuen Mun : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Tuen Mun : GSK Investigational Site

Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib

Budapest : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Budapest : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Debrecen : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Gyor : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Kaposvár : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

View More »

Veszprém : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Andra Pradesh : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Bangalore : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Bangalore N/A : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Bhopa : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Hyderabad : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

View More »

Hyderabad N/A : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Jaipur : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Kerala : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Kolkata : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Lucknow : Pfizer Investigational Site

Open Label Extension In Cancer Patients

Mangalore : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Mumbai : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Nagpur : Pfizer Investigational Site

Open Label Extension In Cancer Patients

Nashik : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Nashik : Pfizer Investigational Site

Open Label Extension In Cancer Patients

Pune : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Tamil Nadu Na : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Tamil Naud : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Trivandrum : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Uttar Pradesh : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Vellore : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Bandung : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Jakarta : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Semarang : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Yogyakarta : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Haifa : Rambam medical Center -The Pain palliation unit

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Haifa : Rambam Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Jerusalem : Hadassah Medical Organization

Evaluation of [18F]-ML-10 as a PET Imaging Radiotracer for Early Detection of Response of Brain Metastases to Stereotactic Radio Surgery

Jerusalem : Shaare-Zedek Medical Centre

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Petach Tikva : Rabin Medical Center

Evaluation of [18F]-ML-10 as a PET Imaging Radiotracer for Early Detection of Response of Brain Metastases to Whole Brain Radiation Therapy

View More »

Petah Tiqva : Rabin Medical Center, Beilinson Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Ramat Gan : Sheba MC

Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System

Ramat Gan : Sheba Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Ramat Gan : Sheba MC

Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma

Tel Aviv : TA Sourasky Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Tel Hashomer : Sheba Medical Center

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Tel-Hashomer : Chaim Sheba - Medical Center

Evaluation of [18F]-ML-10 as a PET Imaging Radiotracer for Early Detection of Response of Brain Metastases to Stereotactic Radio Surgery

Aviano : Irccs Centro Di Riferimento Oncologico (Cro) - Aviano

131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors

Bergamo : Ospedali Riuniti Di Bergamo

131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors

Bologna : A.O.U. die Bologna

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bologna : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Bologna : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

View More »

Candiolo (to) : 1200.67.39004 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Chieti : Università G. d'Annunzio

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Firenze : Azienda Ospedaliero UNIVERSITARIA CAREGGI DI FIRENZE

131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors

Firenze : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Genova : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Macerata : ASUR Zona Territoriale 9, Medicina Nucleare Ospedale di Macerata

131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors

Meldola (FC) : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Messina : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Milano : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Modena : 1200.67.39001 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Monza : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Napoli : Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale Di Napoli

131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors

Napoli : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Padova : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Perugia : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Pisa : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Pordenone : Azienda Ospedaliera S.Maria Degli Angeli

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Reggio Emilia : Arcispedale Santa Maria Nuova Di Reggio Emilia

131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors

Reggio Emilia : 1200.67.39002 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Rimini : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Roma : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Roma : Istituto Regina Elena

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Roma : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Rome : University of Rome "La Sapienza"

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Rozzano (mi) : Irccs Istituto Clinico Humanitas

131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors

San Giovanni Rotondo (FG) : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Siena : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Trento : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Treviglio (BG) : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Udine : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Varese : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Kashiwa : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Mitaka-city : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Nagoya-city : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Osaka : Research Site

Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients

Sunto-gun : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

View More »

Tokyo : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Yokohama-city : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Busan : GSK Investigational Site

Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib

Cheonju : Chungbuk University Hospital

Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)

Gangwon-do : GSK Investigational Site

Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib

Goyang : 1200.67.82001 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Goyang-si : National Cancer Center

Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)

View More »

Incheon : GSK Investigational Site

Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib

Kyunggi-do : GSK Investigational Site

Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib

Seoul : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Seoul : 1200.67.82002 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Seoul : 1200.67.82004 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Seoul : 1200.67.82003 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Seoul : Samsung Medical Center

Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)

Seoul : GSK Investigational Site

Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib

songpa-gu, Seoul : GSK Investigational Site

Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib

Kaunas : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Vilnius : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Bitola : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Skopje : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Nilai : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Chihuahua : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Morelia : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Amsterdam : Antoni van Leeuwenhoek Ziekenhuis

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Amsterdam : Vrije Universiteit medisch centrum (Vumc)

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Amsterdam : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Arnhem : Ziekenhuis Rijnstate

Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer

Assen : Wilhelmina Ziekenhuis

Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer

View More »

Eindhoven : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Eindhoven : Catharina-Ziekenhuis

Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer

Groningen : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Leiden : Leids Universitair Medisch Centrum (LUMC)

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Leiden : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Rotterdam : Erasmus MC

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Rotterdam : Ikazia Ziekenhuis

Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer

Utrecht : Universitair Medisch Centrum Utrecht

Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer

Veldhoven : Maxima Medisch Centrum

Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer

Venlo : VieCuri MC

Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer

Winterswijk : Streekziekenhuis Koningin Beatrix

Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer

Auckland : University of Auckland

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Christchurch : Christchurch Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Dunedin : Dunedin Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Newtown : Wellington Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Palmerston : Palmerston North Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Cebu : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Davao City : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Quezon City : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Bydgoszcz : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Gdansk : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Gliwice : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Konin : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Konin : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

View More »

Lodz : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Lodz : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Olsztyn : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Poznan : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Poznan : Pfizer Investigational Site

Open Label Extension In Cancer Patients

Rzeszow : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Warsaw : Wojskowy Instytut Medyczny (WIM)

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Warszawa : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Warszawa : Research Site Updated

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Wloclawek : Pfizer Investigational Site

Open Label Extension In Cancer Patients

Wroclaw : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Amadora : Hospital Fernando Fonesca

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Barreiro : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Coimbra : Hospitais da Universidade de Coimbra

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Lisboa : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Porto : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Bucuresti : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Cluj Napoca : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Cluj-Napoca : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Sibiu : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Arkhangelsk : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Arkhangelsk : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Belgorod : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Chelyabinsk : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Chelyabinsk : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

View More »

Chelyabinsk : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Kazan : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Kazan : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Kirov : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Lening : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Moscow : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Moscow : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Moscow : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Moscow N/A : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Moscow Region : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Nizhniy Novgorod : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Obninsk : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Obninsk : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Orenburg : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Perm : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Pyatigorsk : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Rostov on Don : Rostov State Research Institute of Oncology

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Ryazan : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Saint Petersburg : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Samara : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Smolensk : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

St Petersburg : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

St Petersburg N/A : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

St. Petersburg : N. N. Petrov Institute of Oncology

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

St. Petersburg : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Tver : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Ufa : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Velikiy Novgorod : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Voronezh : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Voronezh : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Belgrade : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Sremska Kamenica : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Singapore : GSK Investigational Site

Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib

Bardejov : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Bratislava : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Kosice : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Nitra : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Poprad : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Ljubljana : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

A Coruña : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Badalona : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Barcelona : Updated

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Barcelona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Barcelona : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

View More »

Barcelona : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Barcelona : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Barcelona : 1200.67.34002 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Cáceres : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Elche : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Hospitalet de Llobregat (Barcelona) : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Jerez (Cadiz) : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

La Coruña : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Lerida : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Madrid : Updated

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Madrid : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Madrid : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Madrid : 1200.67.34003 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Madrid : Spanish Cooperative Group for Gastrointestinal Tumour Therapy

Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases

Málaga : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Palma de Mallorca : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Pamplona : Hospital de Navarra, Servicio de Ongoligia, Planta Baja

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Pamplona : Clinica Universitaria de Navarra

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Sanchinarro : Updated

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Santander : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Santiago de Compostela : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Sevilla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Sevilla : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Valencia : 1200.67.34004 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Valencia : 1200.67.34001 Boehringer Ingelheim Investigational Site

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Eskilstuna : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Linköping : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Stockholm : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Uppsala : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Uppsala : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

View More »

Västerås : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Växjö : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Basel : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Geneva 14 : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Winterthur : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Zurich : University Hospital Zurich

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Zurich : Universitatsspital Zurich

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Changhua : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Gueishan Township : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Kaohsiung : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Niaosong Township : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Taichung : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

View More »

Tainan : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Taipei City : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Bangkok : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Chiangmai : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Songkla : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Dnepropetrovsk : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Donetsk : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Ivano-Francovsk : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Kiev : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Lviv : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

View More »

Odessa : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Uzhgorod : Updated

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Aberdeen : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Belfast : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Birmingham : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Cottingham : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Edinburgh : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

View More »

Huddersfield : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Ipswich : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Leicester : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

London : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Maidstone : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Manchester : Christie Hospital

EMD 525797 in Colorectal & Ovarian Cancer Patients With Liver Metastases

Manchester : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Northampton : Research Site Updated

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Northwood : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Nottingham : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Peterborough : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Sheffield : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Shrewsbury : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Southampton : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Wolverhampton : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Worthing : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Washington : Georgetown University

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Washington : Lombardi Comprehensive Cancer Center/Gerogetown University Hospital

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Washington : Washington Cancer Institute

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Washington : GSK Investigational Site

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.